DURAVYU (vorolanib intravitreal insert) — Topline data
Q4 2026
The Company remains on track to report topline data from the second wet AMD pivotal Phase 3 LUCIA trial in the fourth quarter of 2026.Source filing
EYPT biotech catalysts & pipeline
EYEPOINT INC · Data as of 2026-09-08
Upcoming catalysts
DURAVYU (vorolanib intravitreal insert) — NDA/BLA submission
1H 2027
Topline data from LUCIA, the second pivotal Phase 3 clinical trial in wet AMD, expected in Q4 2026 with potential FDA New Drug Application submission planned for 1H 2027 –Source filing
DURAVYU (vorolanib intravitreal insert) — Topline data
Q4 2027
Pivotal data from the Phase 3 DME program is anticipated to be reported in the fourth quarter of 2027.Source filing
DURAVYU (vorolanib intravitreal insert) — Conference presentation
Sep 23–Sep 26
EyePoint plans to present additional details on the LUGANO dataset, including subgroup-analyses, at major retina conferences in the coming months, beginning at the Retina Society 59 th Annual Scientific Meeting from September 23-26, 2026.Source filing